Company Description
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.
It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass forming machines; and after-sales services, such as spare parts and maintenance services.
It also provides contract development and manufacturing services for customer-owned drug delivery devices.
The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug product, glass packaging, and fill and finish contract manufacturers.
The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
| Country | Italy |
| Founded | 1949 |
| IPO Date | Jul 16, 2021 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 5,521 |
| CEO | Franco Stevanato |
Contact Details
Address: Via Molinella 17 Piombino Dese, PD 35017 Italy | |
| Phone | 39 04 99 31 811 |
| Website | stevanatogroup.com |
Stock Details
| Ticker Symbol | STVN |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $21.00 |
| CIK Code | 0001849853 |
| CUSIP Number | T9224W109 |
| ISIN Number | IT0005452658 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Franco Stevanato | Chief Executive Officer and Executive Chairman |
| Marco Dal Lago | Chief Financial Officer |
| Lisa Miles | Chief Communications and Investor Relations Officer |
| Carla Costa | Chief Human Resources Officer |
| Mauro Stocchi | Chief Business Strategy Officer |
| Ugo Gay | President of DCS Business Unit and Shared Services |
| Michele Monico | President of DDS and IVD Business Unit |
| Raffaele Pace | President of Engineering Business Unit |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 12, 2025 | 6-K | Report of foreign issuer |
| Aug 12, 2025 | SCHEDULE 13G | Filing |
| Aug 5, 2025 | 6-K | Report of foreign issuer |
| Aug 5, 2025 | 6-K | Report of foreign issuer |
| Aug 5, 2025 | 6-K | Report of foreign issuer |
| Jun 12, 2025 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Jun 11, 2025 | 144 | Filing |
| Jun 10, 2025 | 6-K | Report of foreign issuer |
| Jun 5, 2025 | SD | Form - SD |
| May 13, 2025 | 6-K | Report of foreign issuer |